Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 2 3Phase 3 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Sarcoma 1

Conditions

Lymphoma 2Leukemia 2Hyperuricemia 2Nutritional and Metabolic Diseases 1Lymphoma, Large B-Cell, Diffuse 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × Urate Oxidase × Clear all
NCT00057811 2014-09-19

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Children's Oncology Group

Phase 2 Completed
97 enrolled 13 charts
LymphoidSarcoma

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT00631579 2009-10-02

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Sanofi

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Hyperuricemia

NCT00290992 2009-03-30

Rasburicase for Hyperuricemia

Sanofi

Phase 2 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nutritional and Metabolic Diseases, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡